Share on LinkedInShare on LinkedIn

ARTICLE · 03 JUNE 2026

Extending Protection For Pharmaceuticals | Requirements In Australia, China And Singapore

Spruson & Ferguson's intellectual property experts provide insights into patent examination processes and strategies for navigating complex IP landscapes across multiple jurisdictions. The team offers guidance on maximizing patent protection while addressing technical and legal challenges that arise during prosecution.

AustraliaIntellectual Property

Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data exclusivity in Australia, China, and Singapore.

 A comparison table is provided below which summarises key requirements and timing considerations for both PTEs and data exclusivity. 

At the end of the article, we have provided a link to download this information as a pdf. You may also share the article via the buttons under the download option.

Australia 

Patent term extension   

Australia’s Patents Act provides an extension of up to 5 years beyond the standard 20-year term for certain pharmaceutical patents.  

To be eligible for a patent term extension (PTE), the following criteria must be met:  

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from